MX2020013734A - Formulaciones de tiosulfato de sodio anhidro. - Google Patents

Formulaciones de tiosulfato de sodio anhidro.

Info

Publication number
MX2020013734A
MX2020013734A MX2020013734A MX2020013734A MX2020013734A MX 2020013734 A MX2020013734 A MX 2020013734A MX 2020013734 A MX2020013734 A MX 2020013734A MX 2020013734 A MX2020013734 A MX 2020013734A MX 2020013734 A MX2020013734 A MX 2020013734A
Authority
MX
Mexico
Prior art keywords
anhydrous sodium
sodium thiosulfate
formulations
methods
ototoxicity
Prior art date
Application number
MX2020013734A
Other languages
English (en)
Inventor
Thomas Claiborne Lovelace
Iii Joseph Alexander Moore
Christopher Mckinnon Lee
Daniel Logan Kirschner
Original Assignee
Fennec Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69060534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020013734(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fennec Pharmaceuticals Inc filed Critical Fennec Pharmaceuticals Inc
Publication of MX2020013734A publication Critical patent/MX2020013734A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00—Sulfur; Compounds thereof
    • C01B17/64—Thiosulfates; Dithionites; Polythionates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

En la presente se describe tiosulfato de sodio anhidro, métodos para sintetizar tiosulfato de sodio anhidro, composiciones farmacéuticas de este y métodos para tratar la ototoxicidad. El tiosulfato de sodio anhidro se sintetiza a partir de sulfito de sodio, azufre y cloruro de cetilpiridinio. El tiosulfato de sodio anhidro se formula en una composición farmacéutica que comprende un amortiguador y un solvente. Estas composiciones son útiles para eliminar o reducir la ototoxicidad en pacientes pediátricos que reciben agentes quimioterapéuticos basados en platino.
MX2020013734A 2018-07-03 2019-07-01 Formulaciones de tiosulfato de sodio anhidro. MX2020013734A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693502P 2018-07-03 2018-07-03
US201862693503P 2018-07-03 2018-07-03
PCT/US2019/040052 WO2020009954A1 (en) 2018-07-03 2019-07-01 Formulations of anhydrous sodium thiosulfate

Publications (1)

Publication Number Publication Date
MX2020013734A true MX2020013734A (es) 2021-05-27

Family

ID=69060534

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013733A MX2020013733A (es) 2018-07-03 2019-07-01 Tiosulfato de sodio anhidro y formulaciones de este.
MX2020013734A MX2020013734A (es) 2018-07-03 2019-07-01 Formulaciones de tiosulfato de sodio anhidro.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020013733A MX2020013733A (es) 2018-07-03 2019-07-01 Tiosulfato de sodio anhidro y formulaciones de este.

Country Status (13)

Country Link
US (15) US20200023003A1 (es)
EP (2) EP3817751A4 (es)
JP (2) JP2021530420A (es)
KR (2) KR20210027409A (es)
CN (2) CN112805238A (es)
AU (2) AU2019299216A1 (es)
BR (2) BR112021000022A2 (es)
CA (2) CA3103986A1 (es)
IL (2) IL279857A (es)
MA (2) MA53101A (es)
MX (2) MX2020013733A (es)
SG (2) SG11202013199UA (es)
WO (2) WO2020009954A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019218232A1 (en) 2018-02-09 2020-09-24 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
AU2019299216A1 (en) 2018-07-03 2021-01-07 Fennec Pharmaceuticals, Inc. Anhydrous sodium thiosulfate and formulations thereof
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
CN114848597A (zh) * 2022-07-11 2022-08-05 北京中科利华医药研究院有限公司 一种双室袋包装的硫代硫酸钠注射液和应用
CN116062708A (zh) * 2022-12-02 2023-05-05 东南大学 一种硫代硫酸钠的合成方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191512599A (en) * 1915-09-02 1916-09-04 Thomas William Staine Hutchins Improvements in the Process for the Manufacture of Sodium Thiosulphate.
US2635980A (en) * 1950-02-11 1953-04-21 Wm S Merrell Co Stabilized sulfa drug
GB713559A (en) * 1951-12-14 1954-08-11 Kodak Ltd Improvements in the manufacture of the thiosulphates and seleno-sulphates of the alkali metals, calcium and ammonium
US2763531A (en) * 1952-11-29 1956-09-18 Eastman Kodak Co Manufacture of sodium thiosulphate from sodium sulfite and sulfur in presence of cationic surface active organic bromides
DE2851037C2 (de) * 1978-11-25 1980-10-02 Dr. Franz Koehler Chemie, 6146 Alsbach Verfahren zur Stabilisierung von für medizinische Zwecke bestimmten Natriumthiosulfat-Lösungen
US4778519A (en) 1987-02-24 1988-10-18 Batric Pesic Recovery of precious metals from a thiourea leach
JP5242877B2 (ja) 2000-04-26 2013-07-24 オレゴン ヘルス アンド サイエンス ユニバーシティー チオールをベースとする化学保護剤の投与
CN100411683C (zh) * 2002-05-21 2008-08-20 阿斯比奥制药株式会社 含有生长素释放肽的药物组合物
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
US20070059382A1 (en) 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
EP2321351B1 (en) 2008-08-18 2017-11-01 Pfizer Inc. Antibodies to ccr2
CA2767168C (en) 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
KR20140121827A (ko) * 2011-12-23 2014-10-16 메르사나 테라퓨틱스, 인코포레이티드 퓨마질린 유도체-phf 결합체의 약제학적 제형
EP2846873B1 (fr) * 2012-05-10 2017-07-12 Institut National de la Santé et de la Recherche Medicale Thiosulfate de sodium pour le traitement des calcifications ectopiques
JP5478680B2 (ja) 2012-08-23 2014-04-23 小林製薬株式会社 水溶性高分子増粘剤を含有する組成物の安定化剤
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US20170204316A1 (en) 2013-09-16 2017-07-20 Basf Enzymes Llc Controlled break enzyme formulations
WO2015058069A1 (en) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
CN103922292A (zh) * 2014-04-29 2014-07-16 辽宁石化职业技术学院 硫代硫酸钠的制备方法
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
US10392371B2 (en) * 2015-10-01 2019-08-27 Senomyx, Inc. Compounds useful as modulators of TRPM8
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
NZ741553A (en) 2015-10-30 2019-08-30 Inception 3 Inc Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
US20170087199A1 (en) 2016-02-10 2017-03-30 Senomyx, Inc. Compositions for delivering a cooling sensation
WO2018005830A1 (en) * 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
US20160376263A1 (en) 2016-07-26 2016-12-29 Senomyx, Inc. Bitter taste modifiers including substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones and compositions thereof
CN107963614A (zh) * 2016-10-20 2018-04-27 王亚玲 一种快速制备高纯度硫代硫酸钠晶体的方法
CN106379867A (zh) * 2016-10-21 2017-02-08 金川集团股份有限公司 一种生产五水硫代硫酸钠的方法
JP7416622B2 (ja) 2017-03-08 2024-01-17 ホープ メディカル エンタープライズ インコーポレイテッド ディー．ビー．エー． ホープ ファーマシューティカルズ チオ硫酸ナトリウムの透析中の使用
WO2018226942A1 (en) 2017-06-08 2018-12-13 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
EP3810146A4 (en) * 2018-04-25 2022-08-17 Otonomy, Inc. OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY
AU2019299216A1 (en) 2018-07-03 2021-01-07 Fennec Pharmaceuticals, Inc. Anhydrous sodium thiosulfate and formulations thereof
US10813947B1 (en) * 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Also Published As

Publication number Publication date
US20240165237A1 (en) 2024-05-23
SG11202013199UA (en) 2021-01-28
EP3817751A4 (en) 2022-05-11
US20200023003A1 (en) 2020-01-23
MA53101A (fr) 2021-05-12
BR112021000022A2 (pt) 2021-03-30
WO2020009954A1 (en) 2020-01-09
US20200009255A1 (en) 2020-01-09
US11964018B2 (en) 2024-04-23
CA3103982A1 (en) 2020-01-09
BR112021000021A2 (pt) 2021-03-30
AU2019299216A1 (en) 2021-01-07
EP3818010A1 (en) 2021-05-12
CA3103986A1 (en) 2020-01-09
CN112805238A (zh) 2021-05-14
AU2019299217A1 (en) 2021-01-14
US20230158145A1 (en) 2023-05-25
CN112805014A (zh) 2021-05-14
US20240042036A1 (en) 2024-02-08
US20230094886A1 (en) 2023-03-30
SG11202013220SA (en) 2021-01-28
MA53102A (fr) 2022-05-11
IL279856A (en) 2021-03-01
US20220323586A1 (en) 2022-10-13
US20230201351A1 (en) 2023-06-29
US20230094842A1 (en) 2023-03-30
US11998604B2 (en) 2024-06-04
US11291728B2 (en) 2022-04-05
EP3818010A4 (en) 2022-08-17
US11992530B2 (en) 2024-05-28
IL279857A (en) 2021-03-01
JP2021530462A (ja) 2021-11-11
US10792363B2 (en) 2020-10-06
US20210015923A1 (en) 2021-01-21
WO2020009953A1 (en) 2020-01-09
US20230201349A1 (en) 2023-06-29
US20240216511A1 (en) 2024-07-04
US20220160875A1 (en) 2022-05-26
US20230201350A1 (en) 2023-06-29
JP2021530420A (ja) 2021-11-11
KR20210027410A (ko) 2021-03-10
EP3817751A1 (en) 2021-05-12
KR20210027409A (ko) 2021-03-10
MX2020013733A (es) 2021-05-27
US11510984B2 (en) 2022-11-29
US20220378915A1 (en) 2022-12-01
US11617793B2 (en) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2020013733A (es) Tiosulfato de sodio anhidro y formulaciones de este.
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PH12020551305A1 (en) Pharmaceutical Compounds
CR20210627A (es) Derivados de benzisoxazol sulfonimada
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
MEP11708A (en) Dimethoxy docetaxel acetone solvate et method for the preparation thereof
DE60329073D1 (de) Edg-rezeptoragonisten
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
MX2021007085A (es) Variante de interleucina-2 humana o derivado de la misma.
EA034243B9 (ru) Фармацевтические композиции, содержащие azd9291, для лечения рака
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA201791667A1 (ru) Соединения бензоксаборола и их применение
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
EA200600694A1 (ru) Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
MX2021009206A (es) Terapias contra el cancer.
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения